RenRen Applied Cell Biotechnology

RenRen Applied Cell Biotechnology is a Chinese biopharmaceutical company focused on the development of next-generation cell therapies for the treatment of solid tumors and hematological malignancies. The company leverages its proprietary platforms to engineer Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies designed to overcome the immunosuppressive microenvironment of solid tumors. RenRen Applied Cell is particularly active in the development of universal, off-the-shelf cell products (UCAR-T) to improve accessibility and reduce manufacturing costs. Their research pipeline targets high-unmet-need indications such as pancreatic, ovarian, and liver cancers.